Targacept, AstraZeneca Face Another Failure With NNR Class

The Targacept/AstraZeneca partnership faces another major setback as they decide not to file their neuronal nicotinic receptor modulator TC-5214 in major depressive disorder. Targacept CEO chalks the trial failure up to the gray areas of depression trial design.

The decision to back away from the development program for TC-5214 in major depression, partnered with AstraZeneca PLC, puts more pressure on Targacept Inc.’s remaining neuronal nicotinic receptor modulator programs; it is the second failure for an NNR drug partnered by the two companies.

The firms announced March 20 that they are ceasing pursuit of approval of TC-5214 for major depressive disorder following another...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

More from R&D